Clinical trial · no report yet · Phase 3
Oligo-PRESTO
Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients
- NCT04115007 ↗
- Active, not recruiting
- UNICANCER
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients - a GETUG-AFU Phase III Randomized Controlled Trial
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Oligometastatic Hormone Sensitive Prostate Cancer
- Interventions
- Stereotactic Body Radiotherapy (SBRT) + Standard of care; Standard of care
- Arms
- Arm A · Experimental
- Arm B · Active comparator
- Enrollment
- 550 (estimated)
- Primary outcomes
- Castration-resistant prostate cancer free survival
- Sponsor
- UNICANCER
- Start
- Jun 23, 2020
- Primary completion
- Jun 23, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04115007 · updated Jun 26, 2025
Publications
linked from the registry- Petrelli F, Ghidini A, Ghidini M, Bukovec R, Trevisan F, Turati L, Indini A, Seghezzi S, Lonati V, Moleri G, Tomasello G, Zaniboni A. Better survival of patients with oligo- compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies. F1000Res. 2021 May 27;10:423. doi: 10.12688/f1000research.52546.4. eCollection 2021. PubMed 35602670